Listed companies have carried out a intensive buyback this week! Wuxi apptec has launched its third "cancellation-style" buyback plan of the year, with a maximum buyback amount of 0.1 billion yuan A-share. Here is a list of the names.
①This week, the A-share listed companies continue to buy back stocks. According to incomplete statistics from Caixin, 11 listed companies plan to repurchase up to 0.1 billion yuan (see table); ②wuxi apptec, following the completion of the first two repurchase plans on February 5 and May 22, announced another 1 billion yuan repurchase plan on Tuesday evening. After the repurchase is completed, all repurchased shares will be cancelled and the registered capital will be reduced.
The business integration is still in the planning stage! 9 days, 6 boards, central enterprise reform concept stocks disclose abnormal announcements | Summary of post-market announcements.
hanjia design group, which has two consecutive trading limits: the transfer of control has uncertainties.
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
CRO Enterprise Yangguang Nuohuo achieved growth against the trend in the first half of the year, but the slowdown in pharmaceutical research and development has brought uncertainty. | Earnings conference
①In the current "cooling off" period in the CRO track, Yangguang Nuohuo achieved performance growth in the first half of the year. Chairman Li Qian said that 80% of the customers are traditional medium to large-sized domestic pharmaceutical companies with stable cash flow and product pipeline needs; ②The research and development targets of Yangguang Nuohuo are mainly generic drugs, supplemented by innovative drugs. With the implementation of policies such as drug consistency evaluation and quantity-based procurement, Yangguang Nuohuo faces the risk of declining performance.
Quick Look at Mid-day Trading | The three major stock indexes in Hong Kong all fell, with oil and coal stocks declining; all three major oil companies saw a drop of over 5%, while Tianqi Lithium Corporation surged 12% against the market trend.
Network technology stocks generally fell, with SenseTime down nearly 3%, JD.com, Netease down nearly 1%, Tencent, Alibaba slightly down; Bilibili rose by over 1%, Meituan slightly rose.
Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.
①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.